North Carolina is currently home to 2648 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
COmmunities Aligned to Reduce Concussion and Head Impact Exposure
NCT06624202
Recruiting
Head impacts in collision sports such as football are a public health concern, as repetitive head impacts, even if a concussion is not suspected, have negative effects on brain health. This study has partnered with a community stakeholder group to create a safety program for youth football named "COmmunities Aligned to reduce Concussion and Head impact exposure (COACH)", which seeks to improve knowledge and skills of youth coaches in effective and safe practice planning and to change attitudes a... Read More
Gender:
ALL
Ages:
Between 11 years and 14 years
Trial Updated:
05/27/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Concussions
Register for Updates
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478
Recruiting
The main purpose of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: East Carolina University, Greenville, North Carolina
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Resident Posture Biofeedback Study
NCT06564519
Recruiting
While a majority of surgical ergonomic studies have been evaluating attending surgeons, few have evaluated surgical ergonomics within the surgical resident. Biofeedback devices can be partnered with education and geared towards surgical residents to decrease current and future musculoskeletal disorders, which may in turn lead to longer and more fulfilling careers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Postural; Strain, Healthy
Register for Updates
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824
Recruiting
This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. Th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Brookview Hills Research Associates LLC, Winston-Salem, North Carolina
Conditions: Kidney Disease, Chronic
Register for Updates
Evaluating Microarray Pharmacogenetic Testing in Cancer Patients
NCT06489041
Recruiting
The purpose of this research is to evaluate the impact of a microarray PGx test on prescribing/dosing of drugs and cancer treatments in patients with cancer who are currently eligible for single-gene DPYD testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Atrium Health Levine Cancer, Charlotte, North Carolina
Conditions: Cancer, Gastrointestinal Cancer
Register for Updates
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288
Recruiting
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every participant has an equal chance of being in each group. The groups are: * Vicadrostat and empagliflozin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Medication Management, LLC, Greensboro, North Carolina
Conditions: Heart Failure
Register for Updates
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT06413498
Recruiting
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM as measured by progression-free survival (PFS) per blinded ind... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Novant Health Cancer Institute Hematology, Charlotte, North Carolina
Conditions: Multiple Myeloma
Register for Updates
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
NCT06334133
Recruiting
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Asheville Clinical Research, Asheville, North Carolina
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
NCT06280950
Recruiting
This is a study to determine the safety, efficacy, and tolerability of taking away the anti-rejection medicine, tacrolimus, in liver transplant recipients in conjunction with everolimus monotherapy to preserve renal function. Two hundred - seventy (270) subjects will be randomized 2:1 into one of two groups between 2-3 months post-transplant. Seventy participants will be placed into an observational group and will remain on their current post-transplant medications. The duration of the study fro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: Duke University Medical Center (Site #: 71139), Durham, North Carolina
Conditions: Liver Transplant
Register for Updates
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
NCT06258902
Recruiting
The participants of this study will be of any age who are exposed to at least 1 dose of odevixibat at any time during pregnancy (from 1 day prior to conception to pregnancy outcome) and/or at any time during lactation (up to 12 months of infant age or weaning, whichever comes first. This study will collect data obtained via a variety of sources, including enrolled pregnant or lactating participants, the healthcare providers (HCP) involved in their care or the care of their infants, if applicabl... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
05/27/2025
Locations: Virtual Research Coordination Center Odevixibat (BYLVAY) Pregnancy Surveillance Program, Wilmington, North Carolina
Conditions: Pregnancy Related
Register for Updates
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
NCT06226571
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of SNDX-5613 in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/27/2025
Locations: Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Acute Myeloid Leukemias
Register for Updates
Obsidio™ Conformable Embolic Registry
NCT06170619
Recruiting
OCCLUDE is a prospective, post-approval, open-label, single arm, multi-center US registry of patients who undergo embolization with Obsidio™ Conformable Embolic. The purpose of this Registry is to assess effectiveness and safety outcomes of subjects who undergo embolization with Obsidio.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of North Carolina Hospital, Chapel Hill, North Carolina
Conditions: Hypervascular Tumors, Bleeding, Hemorrhage
Register for Updates